| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/31/2003 | WO2003015825A3 Conjugate |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003006607A3 Inhibition of apoptosis process and improvement of cell performance |
| 07/31/2003 | WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 07/31/2003 | WO2003004607A3 Aggrecanase molecules |
| 07/31/2003 | WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use |
| 07/31/2003 | WO2002060936A3 Vaccine and compositions for the prevention and treatment of neisserial infections |
| 07/31/2003 | WO2002059292A3 Functional balanced-lethal host-vector systems |
| 07/31/2003 | WO2002059148A3 A method for identification, isolation and production of antigens to a specific pathogen |
| 07/31/2003 | WO2002048362A3 Embryogenesis associated proteins |
| 07/31/2003 | WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 07/31/2003 | WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/31/2003 | WO2002038742A3 Dipeptidylpeptidases and methods of use |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002018444A3 Erbb4 antagonists |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2001095942A3 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 07/31/2003 | WO2001062298A9 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/31/2003 | US20030144486 Monoclonal human natural antibodies |
| 07/31/2003 | US20030144485 Monoclonal human natural antibodies |
| 07/31/2003 | US20030144482 Diagnosis of skin cancer; vaccine |
| 07/31/2003 | US20030144479 Biologically active compounds and methods of constructing and using the same |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144473 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases |
| 07/31/2003 | US20030144240 Antisense strategy to modulate estrogen receptor response (ER alpha and/or ER beta) |
| 07/31/2003 | US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144198 Increasing gastrointestinal absorption |
| 07/31/2003 | US20030144197 Autologous growth factor cocktail composition, method of production and use |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143735 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 07/31/2003 | US20030143717 Peroxygen compound and an organic acid, composition having an acidic pH; for bird vaccines against coccidiosis |
| 07/31/2003 | US20030143685 Nucleic acid expression control sequence cassettes comprising a stable bacteriophage T5 promoter and nucleic acid regulatory sequences, useful for generating stable expressin vectors of high-level protein expression; culture product |
| 07/31/2003 | US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 07/31/2003 | US20030143672 Providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes, useful in eliciting immune responses with respect to corresponding wildtype epitopes |
| 07/31/2003 | US20030143667 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 07/31/2003 | US20030143647 Anticancer vaccine and diagnostic methods and reagents |
| 07/31/2003 | US20030143621 Contacting a cellular component with a reagent which binds to PC-1 (prostate cancer-1) protein |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143248 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 07/31/2003 | US20030143245 Multivalent streptococcal vaccine compositions and methods for use |
| 07/31/2003 | US20030143243 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 07/31/2003 | US20030143242 For use in vaccination; prophylaxis and therapy of Helicobacter infection |
| 07/31/2003 | US20030143241 For inhibiting hepatitis E virus (HEV) infection |
| 07/31/2003 | US20030143240 Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| 07/31/2003 | US20030143239 Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use |
| 07/31/2003 | US20030143238 Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| 07/31/2003 | US20030143237 Creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule; where immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against cancer cells |
| 07/31/2003 | US20030143236 For irreversibly inhibiting infectivity of a mammalian cell by a human rhinovirus |
| 07/31/2003 | US20030143234 For therapy of microbial organism infection |
| 07/31/2003 | US20030143233 For use in diagnosis, therapy |
| 07/31/2003 | US20030143231 Assaying the ability of the compound to modulate 57749 nucleic acid expression or 57749 polypeptide activity, thereby identifying a compound capable of treating a pain disorder |
| 07/31/2003 | US20030143228 Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
| 07/31/2003 | US20030143225 Administering a dose of anti-tissue factor antibody and a suboptimal dose of at least one additional anticoagulant selected from the group consisting of heparin, low molecular weight heparin, pentasaccharide thrombin inhibotrs |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143221 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant |
| 07/31/2003 | US20030143216 For therapy of fungal infections; for detecting chitin, binding chitin |
| 07/31/2003 | US20030143213 Methods for increasing a cytotoxic T lymphocyte response in vivo |
| 07/31/2003 | US20030143201 For inducing protective immune response, thereby enhancing protection of the individual against subsequent infection by western equine encephalitis virus |
| 07/31/2003 | US20030143194 Antagonists of HMG1 for treating inflammatory conditions |
| 07/31/2003 | US20030143193 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 07/31/2003 | US20030143160 Administering conjugate of the entity and a light-generating moiety; immobilizing the subject within the detection field of a photodetector device; measuring photon emission with photodetectorl; constructing image |
| 07/31/2003 | CA2840490A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2753899A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474623A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | CA2474259A1 Antibodies against and compositions containing new amphetamine derivatives |
| 07/31/2003 | CA2473746A1 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/31/2003 | CA2473717A1 Dna dosage forms |
| 07/31/2003 | CA2473679A1 Dna dosage forms |
| 07/31/2003 | CA2473474A1 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | CA2472775A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472186A1 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | CA2471727A1 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations |
| 07/31/2003 | CA2454358A1 Multimeric proteins and methods of making and using same |
| 07/31/2003 | CA2452545A1 West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus |
| 07/30/2003 | EP1331271A1 The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits |
| 07/30/2003 | EP1331270A1 Novel recombinant feline herpesvirus 1 and polyvalent vaccine with the use of the same |
| 07/30/2003 | EP1331266A1 Cells producing antibody compositions |
| 07/30/2003 | EP1330766A2 Method for designing protein libraries with altered immunogenicity |
| 07/30/2003 | EP1330543A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 07/30/2003 | EP1330538A2 Cd36 as a heat shock protein receptor and uses thereof |
| 07/30/2003 | EP1330531A2 Influenza virus vector for infection of dendritic cells |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330515A1 Methods of agonizing and antagonizing fabk |
| 07/30/2003 | EP1330473A2 Streptococcal genes |
| 07/30/2003 | EP1330469A2 Glycoproteins and methods of use therefof |
| 07/30/2003 | EP1330264A2 Vaccine for treating allergy |
| 07/30/2003 | EP1330263A2 Method for down-regulating ige |
| 07/30/2003 | EP1330260A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 07/30/2003 | EP1330240A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 07/30/2003 | EP1330237A2 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 07/30/2003 | EP0983074B1 Non-myeloablative tolerogenic treatment |
| 07/30/2003 | EP0975362B1 Pharmaceutical or food composition for treating pathologies related to graft versus host, allergic or autoimmune reaction |
| 07/30/2003 | EP0942780B1 Coated particles, methods of making and using |